Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02801448
Other study ID # BSE1
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 2015
Est. completion date June 2020

Study information

Verified date January 2022
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Type 2 diabetes (T2D) results from a combination of insufficient insulin secretion from pancreatic islets and insulin resistance of target cells. The investigators have extensive pre-clinical data suggesting that BSE through its high content of the isothiocyanate sulforaphane improves hepatic insulin sensitivity. BSE as a dietary supplement could therefore benefit both patients with T2D and individuals at risk for the disease. BSE-containing sulforaphane is suggested to activate Nuclear factor-like 2 (NRF2). The investigators aim to study the clinical effect of using BSE as a dietary supplement on glucose tolerance and insulin sensitivity.


Description:

Sulforaphane binds to Keap1 in the cytosol, leading to nuclear translocation of this transcription factor. In the nucleus NRF2 induces the expression of a large number of anti-oxidative genes. Sulforaphane is contained at high concentration in broccoli sprout extracts (BSE). Human studies have been conducted using broccoli sprout products without complication. It is being tested for the treatment or prevention of cancer and inflammatory diseases in ~30 clinical trials without any serious adverse events reported. The low toxicity makes BSE ideal as a dietary supplement for preventing and treating T2D. The investigators aim to study the clinical effect of sulforaphane on glucose tolerance in T2D patients. Sulforaphane will be given as BSE. BSE is a freeze-dried powder of an aqueous extract of broccoli sprouts that provides a consistent and stable source of sulforaphane. The investigators will use a parallel arm study design with patients receiving BSE or placebo. The randomization will be double-blind. The study will be done at one centre. Patients with BMI between 25-40 kg/m2 will be included. Another inclusion criterion is HbA1c 6-10%. Patients will be treated for 12 weeks to enable us to observe effects on HbA1c (HbA1c turn-over is 3 months). Patients will come to a screening visit and if they give informed consent and are included they attend a second visit 2-3 weeks later. The patients will undergo an oral glucose tolerance test (OGTT) before and after the 12-week treatment period. The reason for using OGTT rather than e.g. insulin clamps as the readout is that it is a harmless standard procedure that gives an integrated view of glucose tolerance.


Recruitment information / eligibility

Status Completed
Enrollment 103
Est. completion date June 2020
Est. primary completion date June 2020
Accepts healthy volunteers No
Gender All
Age group 35 Years to 75 Years
Eligibility Inclusion Criteria: - Classified as type 2 diabetes - Written informed consent - Age: for men and women 35-75 years; for women below 75 years should be postmenopausal (defined as no menstrual bleeding since at least one year). - Body mass index 25-40 kg/m2 - At screening visit : HbA1c 6-10 %, equivalent to 41-86 mmol/mol - Currently treated with metformin or diet Exclusion Criteria: - Treatment with insulin, other anti-diabetic treatment given as injections or any oral anti-diabetic treatment except metformin - Fasting blood glucose at screening > 15.0 mmol/L - Active liver disease - At screening or at any subsequent visit a level of aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) of more than three times the upper limit of the normal range - Gastrointestinal ailments which may interfere with the ability to adequately absorb sulforaphane - At screening visit creatinine > 130 µmol/L - Coagulation disorder or current anti-coagulant therapy with warfarin, which may be affected by the BSE - Diagnosed with a cardiovascular disease or event within 6 months prior to enrolment - Systemic glucocorticoid treatment - Herbal treatment, defined as food supplement (except multivitamin treatment) with herbal or vegetable extracts that may contain sulforaphane - Allergy to broccoli - Mental disorder making the patient unable to understand the study information - Participation in other clinical trial which may affect the outcome of the present study - Any other physical or psychiatric condition or treatment that in the judgment of the investigator makes it difficult to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
sulforaphane
sulforaphane-containing broccoli sprout extracts
Placebo
Maltodextrine-based placebo without sulforaphane

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Anders Rosengren, MD PhD

Outcome

Type Measure Description Time frame Safety issue
Primary Delta-HbA1c difference in HbA1c before and after treatment 12 weeks
Secondary Delta-fasting blood glucose difference in fasting blood glucose before and after treatment 12 weeks
See also
  Status Clinical Trial Phase
Withdrawn NCT01377961 - Effect of Lycopene and Isoflavones on Glucose Metabolism N/A
Completed NCT00754130 - MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011). Phase 1
Completed NCT00006305 - Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes Phase 3
Completed NCT00004983 - Education and Group Support for Diabetic Hispanics N/A
Completed NCT00010751 - Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors Phase 2
Completed NCT02299388 - To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study Phase 4
Completed NCT00550329 - Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Phase 1
Completed NCT00172536 - Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft N/A
Completed NCT00071422 - Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes Phase 2
Completed NCT00029848 - Obese Patients With Type 2 Diabetes Phase 3
Completed NCT01608724 - The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT01694758 - OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA N/A
Completed NCT00979368 - Safety Study of BMS-816336 in Healthy Male Subjects Phase 1
Completed NCT00791661 - MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005) Phase 1
Active, not recruiting NCT02088658 - Technology Intensified Diabetes Education Study in African Americans N/A
Completed NCT01105429 - Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes Phase 1
Completed NCT00701090 - A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED) Phase 3
Completed NCT00952991 - The Effects of LAF237 on Gastric Function in Type 2 Diabetes Phase 3
Completed NCT00035984 - Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Phase 3
Completed NCT00044447 - Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione Phase 3